Health Care [ 2/12 ] | Pharmaceuticals [ 6/73 ]
NASDAQ | Common Stock
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally.
The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc.
It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 15, 25 | -1.57 Decreased by -2.34 K% | -0.67 Decreased by -134.33% |
| May 19, 25 | -0.21 Increased by +8.74% | -0.12 Decreased by -74.92% |
| Mar 31, 25 | -0.01 Increased by +94.12% | -0.11 Increased by +90.91% |
| Nov 15, 24 | -0.10 Increased by +52.38% | -0.50 Increased by +80.00% |
| Aug 16, 24 | 0.07 Increased by +131.82% | -0.20 Increased by +135.00% |
| May 20, 24 | -0.23 Increased by +43.90% | -0.15 Decreased by -53.33% |
| Mar 13, 24 | -0.17 Increased by +32.00% | -0.17 |
| Nov 9, 23 | -0.21 Decreased by -40.00% | -0.23 Increased by +8.70% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 17.26 M Increased by +217.71% | 11.61 M Increased by +487.55% | Increased by +67.26% Increased by +84.93% |
| Mar 31, 25 | 1.03 M Increased by +121.24% | -8.81 M Decreased by -38.84% | Decreased by -854.32% Increased by +37.25% |
| Dec 31, 24 | 278.00 K Decreased by -37.81% | -5.85 M Decreased by -20.89% | Decreased by -2.10 K% Decreased by -94.37% |
| Sep 30, 24 | 5.36 M Increased by +2.42 K% | -366.00 K Increased by +93.59% | Decreased by -6.83% Increased by +99.75% |
| Jun 30, 24 | 5.43 M Increased by +814.65% | 1.98 M Increased by +133.10% | Increased by +36.37% Increased by +103.62% |
| Mar 31, 24 | 466.00 K Decreased by -38.52% | -6.34 M Increased by +79.62% | Decreased by -1.36 K% Increased by +66.85% |
| Dec 31, 23 | 447.00 K Increased by +347.00% | -4.84 M Increased by +2.20% | Decreased by -1.08 K% Increased by +78.12% |
| Sep 30, 23 | 213.00 K Decreased by -18.39% | -5.71 M Decreased by -92.22% | Decreased by -2.68 K% Decreased by -135.54% |